Kymera Therapeutics, Inc. vs Pfizer, Inc. — Stock Comparison
Kymera Therapeutics, Inc. (KYMR) and Pfizer, Inc. (PFE) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Pfizer, Inc. narrowly edges Kymera Therapeutics, Inc. on Q·Score (5.7 vs 5.4 out of 10), led by Quality (5 vs 2.1) and Valuation (5.9 vs 4.2). Kymera Therapeutics, Inc. scores higher on Sentiment, reflecting stronger analyst and market sentiment. Analyst consensus targets imply greater upside for KYMR (+11.8%) than for PFE (-4.1%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Clean balance sheet with low leverage (0.0× debt-to-equity).
⚠ low return on equity (-27%).
Consistently beats earnings estimates (4/4 quarters).
⚠ cautious analyst consensus — few Buy ratings.
Analyst Consensus
Fundamentals
Frequently Asked Questions
KYMR vs PFE: which stock scores better overall?
Based on Q·Score, Pfizer, Inc. (PFE) scores 5.7/10 versus Kymera Therapeutics, Inc. (KYMR) at 5.4/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: KYMR or PFE?
Pfizer, Inc. (PFE) scores higher on Growth (5.9/10 vs 5/10). Kymera Therapeutics, Inc. reports revenue growth while Pfizer, Inc. reports (2.6% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is KYMR or PFE more attractively valued?
Pfizer, Inc. (PFE) scores higher on Valuation (5.9/10 vs 4.2/10). Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about KYMR vs PFE?
There are 23 analysts covering KYMR with a consensus price target of $141.61, and 26 analysts covering PFE with a consensus target of $29.26. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: KYMR or PFE?
Pfizer, Inc. (PFE) scores higher on Quality (5/10 vs 2.1/10). Net profit margin: KYMR at 0.0%, PFE at 6.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: KYMR or PFE?
Kymera Therapeutics, Inc. (KYMR) scores higher on Financial Health (8.7/10 vs 7/10). Market beta: KYMR at 1.98, PFE at 0.28. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of KYMR and PFE?
Kymera Therapeutics, Inc. (KYMR) has a market capitalisation of $10.8B, while Pfizer, Inc. (PFE) has a market cap of $174.0B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do KYMR or PFE pay dividends?
KYMR does not currently pay a dividend, while PFE pays a dividend yield of 5.64%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →